Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases for $1.2 billion
On Jan. 7, 2025, Eli Lilly and Ventyx Biosciences, a San Diego-based clinical-stage biopharmaceutical company focused on developing…